Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

PHASE3CompletedINTERVENTIONAL
Enrollment

617

Participants

Timeline

Start Date

January 1, 2013

Primary Completion Date

July 1, 2013

Study Completion Date

July 22, 2013

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Umeclidinium bromide 62.5mcg

Inhalation Powder, LAMA 62.5mcg

DRUG

Umeclidinium bromide 125mcg

Inhalation Powder, LAMA 125mcg

DRUG

Fluticasone propionate 250mcg/Salmeterol 50mcg

Inhalation Powder, ICS/LABA

DRUG

Placebo

Inhalation Powder, Placebo

Trial Locations (73)

6682

GSK Investigational Site, Teuchern

13125

GSK Investigational Site, Berlin

13156

GSK Investigational Site, Berlin

14059

GSK Investigational Site, Berlin

19055

GSK Investigational Site, Schwerin

22143

GSK Investigational Site, Hamburg

22299

GSK Investigational Site, Hamburg

22767

GSK Investigational Site, Hamburg

23552

GSK Investigational Site, Lübeck

23858

GSK Investigational Site, Reinfeld

26505

GSK Investigational Site, Morgantown

28844

GSK Investigational Site, Weyhe-Leeste

29379

GSK Investigational Site, Union

29615

GSK Investigational Site, Greenville

29640

GSK Investigational Site, Easley

30159

GSK Investigational Site, Hanover

30173

GSK Investigational Site, Hanover

32174

GSK Investigational Site, Ormond Beach

33765

GSK Investigational Site, Clearwater

34121

GSK Investigational Site, Kassel

35501

GSK Investigational Site, Jasper

39112

GSK Investigational Site, Magdeburg

45355

GSK Investigational Site, Essen

45359

GSK Investigational Site, Essen

47574

GSK Investigational Site, Goch

47904

GSK Investigational Site, Lafayette

51069

GSK Investigational Site, Cologne

52349

GSK Investigational Site, Düren

55435

GSK Investigational Site, Edina

56068

GSK Investigational Site, Koblenz

58452

GSK Investigational Site, Witten

60389

GSK Investigational Site, Frankfurt am Main

63141

GSK Investigational Site, St Louis

63571

GSK Investigational Site, Gelnhausen

70115

GSK Investigational Site, New Orleans

70378

GSK Investigational Site, Stuttgart

74889

GSK Investigational Site, Sinsheim

78229

GSK Investigational Site, San Antonio

91126

GSK Investigational Site, Schwabach

96049

GSK Investigational Site, Bamberg

97504

GSK Investigational Site, Medford

V6J 1S3

GSK Investigational Site, Vancouver

R2K 3S8

GSK Investigational Site, Winnipeg

A0A 1G0

GSK Investigational Site, Bay Roberts

B2N 1L2

GSK Investigational Site, Truro

L7N 3V2

GSK Investigational Site, Burlington

P3E 1H5

GSK Investigational Site, Greater Sudbury

N7T 4X3

GSK Investigational Site, Sarnia

M5G 1N8

GSK Investigational Site, Toronto

M9W 4L6

GSK Investigational Site, Toronto

J8Y 6S8

GSK Investigational Site, Gatineau

J7J 2K8

GSK Investigational Site, Mirabel

H2R 1V6

GSK Investigational Site, Montreal

G1V 4G5

GSK Investigational Site, Québec

G3K 2P8

GSK Investigational Site, Québec

G6W 5M6

GSK Investigational Site, Saint Romuald

J6E 2B4

GSK Investigational Site, Saint-Charles-Borromée

G8T 7A1

GSK Investigational Site, Trois-Rivières

01069

GSK Investigational Site, Dresden

04109

GSK Investigational Site, Leipzg

04103

GSK Investigational Site, Leipzig

04207

GSK Investigational Site, Leipzig

04357

GSK Investigational Site, Leipzig

07548

GSK Investigational Site, Gera

04626

GSK Investigational Site, Schmölln

420-767

GSK Investigational Site, Bucheon-si

361-711

GSK Investigational Site, Cheongju, Chungcheongbuk-do

220-701

GSK Investigational Site, Kangwon-do

130-872

GSK Investigational Site, Seoul

136-705

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

156-707

GSK Investigational Site, Seoul

442-723

GSK Investigational Site, Suwon, Gyeonggi-do

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY